Skip to main content

2 Result(s)

within Takahiro Ebata Remove this filter

and
Your search also matched 9 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity

Include preview-only content

  1. Article

    Open Access

    Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

    Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced mali...

    Shigehisa Kitano, Toshio Shimizu, Takafumi Koyama… in Cancer Chemotherapy and Pharmacology (2021)

    Download PDF (2400 KB) View Article

  2. Article

    Open Access

    Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

    Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1. This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizuma...

    Takahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, Kenji Tamura… in Investigational New Drugs (2020)

    Download PDF (748 KB) View Article